-
Scandinavian Journal of... 1987Tranexamic acid (AMCA) is a potent antifibrinolytic drug occurring in two isomeric forms; the antifibrinolytic potency resides in the transisomeric form. The main action... (Review)
Review
Tranexamic acid (AMCA) is a potent antifibrinolytic drug occurring in two isomeric forms; the antifibrinolytic potency resides in the transisomeric form. The main action of AMCA is blocking of the lysine-binding sites of the plasminogen molecule, which are of importance for the binding to fibrin. This prevents activation of plasminogen by plasminogen activator also absorbed to fibrin. AMCA can be administered perorally or intravenously and is excreted into the urine. It enters tissues and fluids in various concentrations and crosses the placenta. There is no evidence of a thrombogenic effect of AMCA, but in accordance with its action, it prolongs dissolution of fibrin deposits already formed. AMCA is a drug of high clinical value for the treatment of bleedings due to both systemic and local fibrinolysis.
Topics: Animals; Cyclohexanecarboxylic Acids; Humans; Tranexamic Acid
PubMed: 3321402
DOI: No ID Found -
Annals of Emergency Medicine Sep 2022
Topics: Epistaxis; Humans; Tranexamic Acid
PubMed: 35842341
DOI: 10.1016/j.annemergmed.2022.04.032 -
Aesthetic Surgery Journal Aug 2022
Topics: Efficiency; Humans; Operating Rooms; Rhytidoplasty; Tranexamic Acid
PubMed: 35764053
DOI: 10.1093/asj/sjac151 -
Archives of Orthopaedic and Trauma... Jul 2017The purpose of this meta-analysis was to compare the blood loss and complications of intra-articular (IA) with intravenous (IV) tranexamic acid (TXA) for total knee... (Meta-Analysis)
Meta-Analysis Review
BACKGROUND
The purpose of this meta-analysis was to compare the blood loss and complications of intra-articular (IA) with intravenous (IV) tranexamic acid (TXA) for total knee arthroplasty (TKA).
METHODS
A comprehensive search of studies was conducted to identify related articles in Pubmed, Embase, Cochrane central Register of Controlled Trials, springerLink, OVID and the Research published from January 1980 to September 2016. All studies that compared IA TXA with IV TXA application on TKA were included. Main outcomes of the two methods were collected and analyzed by using Review Manager 5.3.
RESULTS
There were 16 randomized controlled trials with 1308 cases met the criteria. Compared with IV TXA, IA TXA had similar blood volume of drainage, hidden blood loss, transfusion rate and complications (P > 0.05). IA TXA had lower total blood loss than IV TXA, and there was significant difference (P < 0.05). Subgroup analysis of total blood loss based on times of IV TXA administration showed that repeat dose of IV TXA had a higher total blood loss and postoperative hemoglobin drop (P < 0.05) than IA TXA. However, single dose of IV TXA had a similar efficacy on total blood loss and postoperative hemoglobin drop (P > 0.05) when compared with IA TXA.
CONCLUSIONS
Both IA TXA and single dose of IV TXA are effective in reducing total blood loss and postoperative hemoglobin drop without increasing complications of DVT or PE. The current meta-analysis suggests that 1.5 g TXA by IA administration or 1 g TXA by IV administration 10 min before tourniquet deflation is effective and safe in patients undergoing TKA.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Humans; Injections, Intra-Articular; Postoperative Complications; Randomized Controlled Trials as Topic; Tranexamic Acid
PubMed: 28378211
DOI: 10.1007/s00402-017-2683-1 -
Clinical and Experimental Dermatology Apr 2019
Topics: Administration, Oral; Adolescent; Adult; Aged; Antifibrinolytic Agents; Female; Humans; Male; Melanosis; Middle Aged; Pigmentation Disorders; Retrospective Studies; Singapore; Tranexamic Acid; Young Adult
PubMed: 30484898
DOI: 10.1111/ced.13831 -
Small (Weinheim An Der Bergstrasse,... Nov 2023Current research on hemostatic materials have focused on the inhibition of visible hemorrhage, however, invisible hemorrhage is the unavoidable internal bleeding that...
Current research on hemostatic materials have focused on the inhibition of visible hemorrhage, however, invisible hemorrhage is the unavoidable internal bleeding that occurs after trauma or surgery, leading directly to a dramatic drop in hemoglobin and then to anemia and even death. In this study, bacterial nanocellulose (BNC) was synthesized and oxidized from the primary alcohols to carboxyl groups, and then grafted with tranexamic acid through amide bonds to construct degradable nanoscale short fibers (OBNC-TXA), which rapidly activated the coagulation response. The hemostatic material is made up of nanoscale short fibers that can be constructed into different forms such as emulsions, gels, powders, and sponges to meet different clinical applications. In the hemostatic experiments in vitro, the composites had significantly superior pro-coagulant properties due to the rapid aggregation of blood cells. In the coagulation experiments with rat tail amputation and liver trauma hemorrhage models, the group treated with OBNC-TXA1 sponge showed low hemorrhage and inhibited invisible hemorrhage in rectus abdominis muscle defect hemorrhage models, with a rapid recovery of hemoglobin values from 128±5.5 to 165±2.6 g L within 4 days. In conclusion, the degradable short fibers constructed from bacterial nano-cellulose achieved inhibition of invisible hemorrhage in vivo.
Topics: Rats; Animals; Tranexamic Acid; Hemorrhage; Hemostatics; Blood Coagulation; Liver Diseases; Hemoglobins
PubMed: 37501326
DOI: 10.1002/smll.202303615 -
BMJ Supportive & Palliative Care Jan 2024To investigate the efficacy and safety of subcutaneously (SC) administered tranexamic acid. (Review)
Review
OBJECTIVES
To investigate the efficacy and safety of subcutaneously (SC) administered tranexamic acid.
METHODS
A retrospective chart review of the use of SC tranexamic acid in a single palliative care centre. We reviewed the use of this approach since it was introduced in our locality 2 years ago. All clinical notes, medication administration records and infusion monitoring documentation were examined to ascertain therapeutic aim, efficacy and tolerability.
RESULTS
SC tranexamic acid was administered to 22 patients. The most common causes of bleeding were coagulopathy (5), bleeding tumours (9) and thrombocytopaenia (5). The therapeutic aim was either to prevent (6) or treat (16) bleeding and was achieved in 17/22 patients. During this 2-year period, our experience evolved resulting in a greater use of short bolus infusions to achieve more rapid control of bleeding events. Both short and continuous SC infusions were well tolerated with no instances of SC site reactions. One patient developed a suspected arterial thrombus in the last hours of life around the time of converting from oral (PO) to SC tranexamic acid.
CONCLUSIONS
SC administration of tranexamic acid appears to be an effective and well tolerated alternative option for the palliative management of bleeding when the PO and intravenous routes are not available. Further research is needed to clarify tranexamic acid's safety in palliative populations.
Topics: Humans; Antifibrinolytic Agents; Hemorrhage; Palliative Medicine; Retrospective Studies; Tranexamic Acid
PubMed: 35121592
DOI: 10.1136/bmjspcare-2021-003427 -
Emergency Medicine Journal : EMJ Aug 2016
Topics: Antifibrinolytic Agents; Emergency Medicine; Humans; Tranexamic Acid
PubMed: 27048316
DOI: 10.1136/emermed-2015-205458 -
JEMS : a Journal of Emergency Medical... May 2016
Topics: Antifibrinolytic Agents; Emergency Medical Services; Hemorrhage; Humans; Tranexamic Acid
PubMed: 27301106
DOI: No ID Found -
The Medical Letter on Drugs and... Sep 1987
Topics: Cyclohexanecarboxylic Acids; Hemophilia A; Hemorrhage; Humans; Premedication; Prospective Studies; Tooth Extraction; Tranexamic Acid
PubMed: 3626975
DOI: No ID Found